Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

@article{Pfaller2011ClinicalBF,
  title={Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.},
  author={Michael A. Pfaller and Daniel J. Diekema and David K. Andes and Maiken Cavling Arendrup and Steven D. Brown and Shawn R. Lockhart and Mary Motyl and David Scott Perlin},
  journal={Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy},
  year={2011},
  volume={14 3},
  pages={164-76}
}
The CLSI established clinical breakpoints (CBPs) for caspofungin (CSF), micafungin (MCF) and anidulafungin (ANF) versus Candida. The same CBP (susceptible (S): MIC ≤ 2 mcg/ml; non-S: MIC > 2 mcg/ml) was applied to all echinocandins and species. More data now allow reassessment of these CBPs. We examined cases of echinocandin failure where both MICs and fks mutations were assessed; wild type (WT) MICs and epidemiological cutoff values (ECVs) for a large Candida collection; molecular analysis of… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 133 extracted citations

Similar Papers

Loading similar papers…